Converge Bio

growth-positive

Converge Bio, an Israeli startup focused on generative AI for drug discovery, has raised $5.5 million in Seed funding led by TLV Partners. The companys platform leverages large language models trained on biological and chemical data to accelerate the development of drugs. Founded in 2024 by Dov Gertz, Oded Kalev, and Iddo Weiner, Converge Bio aims to reduce the time and cost associated with bringing new drugs to market. The platform offers solutions for engineering antibodies, identifying novel drug targets, and designing optimized mRNA vaccines. Converge Bio has partnered with major pharmaceutical companies like Teva and drug discovery firms such as Compugen and BiomX. The funding will support further development and integration of AI in R&D pipelines.

growth-positive

Converge Bio, a generative AI platform focused on drug discovery and development, has secured $5.5 million in seed funding led by TLV Partners. The company uses large language models trained on biological and chemical data to accelerate the development of drugs, reducing the time and cost typically associated with bringing new medications to market. Converge Bios platform offers solutions such as engineering antibodies and designing optimized mRNA vaccines. The company has partnered with major pharmaceutical firms like Teva and innovative drug discovery companies such as Compugen and BiomX. The investment will support Converge Bios mission to integrate AI into biotech and pharma R&D pipelines, transforming drug discovery processes.